

**What is claimed is:**

1. An aqueous micellar formulation comprising a first active agent, selected from water insoluble benzimidazoles, salicylanilides and active derivatives or salts thereof, in combination with a second active agent, selected  
5 from macrocyclic lactones or active derivatives or salts thereof, said formulation being for topical application to animals for the control of internal parasites and also comprising, per litre of formulation:  
from about 100g to about 400g veterinary-acceptable surfactant(s);  
from about 200g to about 750g veterinary-acceptable water-miscible  
10 solvent(s); and  
from about 50g to about 350g of water.
2. A formulation according to Claim 1, wherein said surfactant is selected from polyoxyethylene sorbitan fatty acid esters or combinations thereof.
3. A formulation according to Claim 2, wherein said surfactant is  
15 polyoxyethylene (20) sorbitan monolaurate.
4. A formulation according to any one of Claim 1, wherein said water-miscible solvent is selected from ethanol, isopropanol, benzyl alcohol, glycol ethers, liquid polyoxyethylene glycols, or a mixture of at least two of these solvents.
- 20 5. A formulation according to Claim 4, wherein one or more of the glycol ethers are selected from alkylene or dialkylene glycol monoalkyl ethers.
6. A formulation according to Claim 5, wherein said one or more of glycol ethers are selected from propylene glycol monomethyl ether, diethylene glycol monoethyl ether, and diethylene glycol monobutyl ether.
- 25 7. A formulation according to Claim 4, comprising a glycol ether and a liquid polyethylene glycol as water-miscible solvents.
8. A formulation according to Claim 7, wherein the polyethylene glycol is PEG 200.
9. A formulation according to Claim 1, further comprising from about 5g  
30 to about 50g per litre of formulation of a stabilizer selected from linear anionic surfactants, buffering agents and mixtures thereof.
10. A formulation according to Claim 9, wherein said stabilizer is selected from linear alkyl sulphates, linear alkyl benzene sulphonates, and phosphates, or mixtures thereof.

11. A formulation according to Claim 10, wherein said stabilizer is sodium dodecyl sulphate.

12. A formulation according to Claim 1, comprising about 100g to about 300g surfactant per litre of formulation.

13. A formulation according to Claim 1, comprising from about 300g to about 650g water-miscible solvent(s) per litre of formulation.

14. A formulation according to claim 1, wherein said formulation comprises from about 10g to about 100g per litre of formulation of a liquid polyethylene glycol as a water-miscible solvent.

15. A formulation according to Claim 13, comprising about 450g to about 550g glycol ether(s) selected from alkylene or dialkylene glycol monoalkyl ethers, and about 20g to about 50g of a liquid polyethylene glycol as the one or more water-miscible solvents per litre of formulation.

16. A formulation according to Claim 1, comprising about 150g water per litre of formulation.

17. A formulation according to Claim 1, comprising from about 120g to about 300g benzimidazole, or a derivative thereof, per litre of formulation.

18. A formulation according to Claim 16 or Claim 17, wherein said first active agent is triclabendazole.

19. A formulation according to Claims 1, comprising from about 7.5g to about 20g macrocyclic lactone per litre of formulation.

20. A formulation according to Claim 19, comprising about 15g macrocyclic lactone per litre formulation.

21. A formulation according to Claim 19 or Claim 20, wherein said macrocyclic lactone is ivermectin.

22. A formulation according to Claim 1, comprising, per litre of formulation:

about 180g to about 240g benzimidazole;

about 7.5g to about 20g macrocyclic lactone or an active derivative or salt thereof;

about 150g to about 250g polyoxyethylene (20) sorbitan monolaurate;

about 450g to about 550g diethylene glycol monobutyl ether;

about 20g to about 50g PEG 200;

about 10g to about 30g sodium dodecyl sulphate; and

about 100g to about 200g of water.

23. The formulation of Claim 22 which comprises about 240g triclabendazole and about 15g ivermectin per litre.

24. A method of treating or preventing a diseased or parasite-infested state in a mammal, comprising topically administering to said mammal a micellar  
5 formulation according to Claim 1 or Claim 22, wherein said disease or parasite-infested state comprises a liver fluke infection or infestation, a nematode infection or infestation, or both a liver fluke and a nematode infection or infestation in a mammal.

25. A method according to Claim 24, wherein said mammal is selected  
10 from cattle, sheep, goats, pigs and horses.

26. A method according to Claims 24, wherein said topical application comprises application of the formulation in a band along the lower portion of the back of the mammal.

27. A method according to Claim 26, wherein the formulation is applied to  
15 the mammal over as small a region as possible, while avoiding run-off of the formulation so as to maximise the concentration of active agents per cm<sup>2</sup> of animal surface.

28. A method according to Claim 26, wherein the band of formulation is applied starting from the thoracic vertebrae and proceeding towards the rump of  
20 the animal, and from about 18mg to about 24mg triclabendazole and from about 0.75mg to about 2mg ivermectin are applied per kilogram animal.

29. The method of Claim 28, wherein about 24mg triclabendazole and about 15mg ivermectin are applied per kilogram animal.